Max Kaufmann1, Hayley Evans2, Anna-Lena Schaupp2, Jan Broder Engler1, Gurman Kaur2,3, Anne Willing1, Nina Kursawe1, Charlotte Schubert1, Kathrine E Attfield2, Lars Fugger2,3, Manuel A Friese1. 1. Institut für Neuroimmunologie und Multiple Sklerose, Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. 2. Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK. 3. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), can be suppressed in its early stages but eventually becomes clinically progressive and unresponsive to therapy. Here, we investigate whether the therapeutic resistance of progressive MS can be attributed to chronic immune cell accumulation behind the blood-brain barrier (BBB). METHODS: We systematically track CNS-homing immune cells in the peripheral blood of 31 MS patients and 31 matched healthy individuals in an integrated analysis of 497,705 single-cell transcriptomes and 355,433 surface protein profiles from 71 samples. Through spatial RNA sequencing, we localize these cells in post mortem brain tissue of 6 progressive MS patients contrasted against 4 control brains (20 samples, 85,000 spot transcriptomes). FINDINGS: We identify a specific pathogenic CD161+/lymphotoxin beta (LTB)+ T cell population that resides in brains of progressive MS patients. Intriguingly, our data suggest that the colonization of the CNS by these T cells may begin earlier in the disease course, as they can be mobilized to the blood by usage of the integrin-blocking antibody natalizumab in relapsing-remitting MS patients. CONCLUSIONS: As a consequence, we lay the groundwork for a therapeutic strategy to deplete CNS-homing T cells before they can fuel treatment-resistant progression. FUNDING: This study was supported by funding from the University Medical Center Hamburg-Eppendorf, the Stifterverband für die Deutsche Wissenschaft, the OAK Foundation, Medical Research Council UK, and Wellcome.
BACKGROUND: Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), can be suppressed in its early stages but eventually becomes clinically progressive and unresponsive to therapy. Here, we investigate whether the therapeutic resistance of progressive MS can be attributed to chronic immune cell accumulation behind the blood-brain barrier (BBB). METHODS: We systematically track CNS-homing immune cells in the peripheral blood of 31 MS patients and 31 matched healthy individuals in an integrated analysis of 497,705 single-cell transcriptomes and 355,433 surface protein profiles from 71 samples. Through spatial RNA sequencing, we localize these cells in post mortem brain tissue of 6 progressive MS patients contrasted against 4 control brains (20 samples, 85,000 spot transcriptomes). FINDINGS: We identify a specific pathogenic CD161+/lymphotoxin beta (LTB)+ T cell population that resides in brains of progressive MS patients. Intriguingly, our data suggest that the colonization of the CNS by these T cells may begin earlier in the disease course, as they can be mobilized to the blood by usage of the integrin-blocking antibody natalizumab in relapsing-remitting MS patients. CONCLUSIONS: As a consequence, we lay the groundwork for a therapeutic strategy to deplete CNS-homing T cells before they can fuel treatment-resistant progression. FUNDING: This study was supported by funding from the University Medical Center Hamburg-Eppendorf, the Stifterverband für die Deutsche Wissenschaft, the OAK Foundation, Medical Research Council UK, and Wellcome.
Authors: Patrik L Ståhl; Fredrik Salmén; Sanja Vickovic; Anna Lundmark; José Fernández Navarro; Jens Magnusson; Stefania Giacomello; Michaela Asp; Jakub O Westholm; Mikael Huss; Annelie Mollbrink; Sten Linnarsson; Simone Codeluppi; Åke Borg; Fredrik Pontén; Paul Igor Costea; Pelin Sahlén; Jan Mulder; Olaf Bergmann; Joakim Lundeberg; Jonas Frisén Journal: Science Date: 2016-07-01 Impact factor: 47.728
Authors: Malin Samuelsson; Katarzyna Potrzebowska; Janne Lehtonen; Jason P Beech; Ekatarina Skorova; Heli Uronen-Hansson; Lena Svensson Journal: Sci Signal Date: 2017-12-12 Impact factor: 8.192
Authors: Natalia B Pikor; Jillian L Astarita; Leslie Summers-Deluca; Georgina Galicia; Joy Qu; Lesley A Ward; Susan Armstrong; Claudia X Dominguez; Deepali Malhotra; Brendan Heiden; Robert Kay; Valera Castanov; Hanane Touil; Louis Boon; Paul O'Connor; Amit Bar-Or; Alexandre Prat; Valeria Ramaglia; Samuel Ludwin; Shannon J Turley; Jennifer L Gommerman Journal: Immunity Date: 2015-12-15 Impact factor: 31.745
Authors: Anneli Peters; Lisa A Pitcher; Jenna M Sullivan; Meike Mitsdoerffer; Sophie E Acton; Bettina Franz; Kai Wucherpfennig; Shannon Turley; Michael C Carroll; Raymond A Sobel; Estelle Bettelli; Vijay K Kuchroo Journal: Immunity Date: 2011-12-15 Impact factor: 31.745
Authors: Gijs Kooij; Ronald Backer; Jasper J Koning; Arie Reijerkerk; Jack van Horssen; Susanne M A van der Pol; Joost Drexhage; Alfred Schinkel; Christine D Dijkstra; Joke M M den Haan; Teunis B H Geijtenbeek; Helga E de Vries Journal: PLoS One Date: 2009-12-08 Impact factor: 3.240
Authors: Anna He; Bernd Merkel; James William L Brown; Lana Zhovits Ryerson; Ilya Kister; Charles B Malpas; Sifat Sharmin; Dana Horakova; Eva Kubala Havrdova; Tim Spelman; Guillermo Izquierdo; Sara Eichau; Maria Trojano; Alessandra Lugaresi; Raymond Hupperts; Patrizia Sola; Diana Ferraro; Jan Lycke; Francois Grand'Maison; Alexandre Prat; Marc Girard; Pierre Duquette; Catherine Larochelle; Anders Svenningsson; Thor Petersen; Pierre Grammond; Franco Granella; Vincent Van Pesch; Roberto Bergamaschi; Christopher McGuigan; Alasdair Coles; Jan Hillert; Fredrik Piehl; Helmut Butzkueven; Tomas Kalincik Journal: Lancet Neurol Date: 2020-03-18 Impact factor: 44.182
Authors: J William L Brown; Alasdair Coles; Dana Horakova; Eva Havrdova; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Maria Trojano; Alessandra Lugaresi; Roberto Bergamaschi; Pierre Grammond; Raed Alroughani; Raymond Hupperts; Pamela McCombe; Vincent Van Pesch; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Jeannette Lechner-Scott; Schlomo Flechter; Mark Slee; Vahid Shaygannejad; Eugenio Pucci; Franco Granella; Vilija Jokubaitis; Mark Willis; Claire Rice; Neil Scolding; Alastair Wilkins; Owen R Pearson; Tjalf Ziemssen; Michael Hutchinson; Katharine Harding; Joanne Jones; Christopher McGuigan; Helmut Butzkueven; Tomas Kalincik; Neil Robertson Journal: JAMA Date: 2019-01-15 Impact factor: 56.272
Authors: Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger Journal: Nat Rev Immunol Date: 2022-05-04 Impact factor: 53.106
Authors: Annalisa M Baratta; Adam J Brandner; Sonja L Plasil; Rachel C Rice; Sean P Farris Journal: Front Mol Neurosci Date: 2022-06-23 Impact factor: 6.261
Authors: Nicola Rothammer; Marcel S Woo; Simone Bauer; Lars Binkle-Ladisch; Giovanni Di Liberto; Kristof Egervari; Ingrid Wagner; Undine Haferkamp; Ole Pless; Doron Merkler; Jan Broder Engler; Manuel A Friese Journal: Sci Adv Date: 2022-08-05 Impact factor: 14.957
Authors: Matthew A Burchill; Matthew P Salomon; Lucy Golden-Mason; Amanda Wieland; Ana C Maretti-Mira; Michael Gale; Hugo R Rosen Journal: PLoS Pathog Date: 2021-08-09 Impact factor: 7.464